Coagulation factor Viia composition

Details Coagulation factor Viia composition Coagulation factor Viia composition

2001-10-25

2004-12-21

Weber, Jon P. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S802000, C514S834000, C530S384000, C530S350000, C530S380000, C604S019000, C604S048000, C604S500000

Reexamination Certificate

active

06833352

ABSTRACT:

FIELD OF INVENTION
The invention relates to pharmaceutical compositions for subcutaneous, intramuscular or intradermal administration of coagulation factor VIIa (FVIIa). The invention further relates to pharmaceutical compositions for prolonging the biological half-life of FVIIa in a mammal, preferably a human being by subcutaneous, intramuscular or intradermal injection. The invention also relates to a kit comprising FVIIa and a pharmaceutically acceptable carrier adapted for delivery of an effective dose of FVIIa to a patient in need thereof by subcutaneous, intramuscular or intradermal injection, a method of treatment of a disease affectable by FVIIIa, a method for prolonging the biological half-life of FVIIa in a mammal, and the use of FVIIa for the manufacture of said compositions.
BACKGROUND OF INVENTION
Blood coagulation is a process consisting of a complex interaction of various blood components, or factors, which eventually gives rise to a fibrin clot. Generally, the blood components which participate in what has been referred to as the coagulation “cascade” are proenzymes or zymogens, enzymatically inactive proteins which are converted to proteolytic enzymes by the action of an activator, itself an activated clotting factor. Coagulation factors that have undergone such a conversion are generally referred to as “active factors”, and are designated by the addition of a lower case “a” suffix (e.g., Factor VIIa).
Activated Factor X (“Xa”) is required to convert prothrombin to thrombin, which then converts fibrinogen to fibrin as a final stage in forming a fibrin clot. There are two systems, or pathways, that promote the activation of Factor X. The “intrinsic pathway” refers to those reactions that lead to thrombin formation through utilisation of factors present only in plasma. A series of protease-mediated activations ultimately generates Factor IXa which, in conjunction with Factor VIIIa, cleaves Factor X into Xa. An identical proteolysis is effected by Factor VIIa and its co-factor, tissue factor, in the “extrinsic pathway” of blood coagulation. Tissue factor is a membrane bound protein and does not normally circulate in plasma. Upon vessel disruption, however, it can complex with Factor VIIa to catalyse Factor X activation or Factor IX activation in the presence of Ca
++
and phospholipid (Nemerson and Gentry,
Biochem
. 25:4020-4033 (1986)). While the relative importance of the two coagulation pathways in haemostasis is unclear, in recent years Factor VII and tissue factor have been found to play a pivotal role in the regulation of blood coagulation.
Factor VII is a trace plasma glycoprotein that circulates in blood as a single-chain zymogen. The zymogen is catalytically inactive (Williams et al.,
J. Biol. Chem
. 264:7536-7543 (1989); Rao et al.,
Proc. Natl. Acad. Sci. USA
. 85:6687-6691 (1988)). Single-chain Factor VII may be converted to two-chain Factor VIIa by Factor Xa, Factor XIIa, Factor IXa or thrombin in vitro. Factor Xa is believed to be the major physiological activator of Factor VII. Like several other plasma proteins involved in haemostasis, Factor VII is dependent on vitamin K for its activity, which is required for the &ggr;-carboxylation of multiple glutamic acid residues that are clustered in the amino terminus of the protein. These &ggr;-carboxylated glutamic acids are required for the metal-associated interaction of Factor VII with phospholipids.
The conversion of zymogen Factor VII into the activated two-chain molecule occurs by cleavage of an internal peptide bond located approximately in the middle of the molecule. In human Factor VII, the activation cleavage site is at Arg
152
-Ile
153
(Hagen et al.,
Proc. Natl. Acad. Sci. USA
83: 2412-2416 (1986); Thim et al.,
Biochem
. 27:7785-7793 (1988) both of which are incorporated herein by references). Bovine Factor VII is activated by cleavage at the analogous Arg
152
-Ile
153
bond (Takeya et al.,
J. Biol. Chem
. 263: 14868-14877, 1988). In the presence of tissue factor, phospholipids and calcium ions, the two-chain Factor VIIa rapidly activates Factor X or Factor IX by limited proteolysis.
Coagulation factors are large proteins that are normally given intravenously to make the medicament directly available in the bloodstream. It would however be advantageous if a medicament could be given subcutaneously, intramuscularly or intradermally as these administration forms are much easier to handle for the patient, especially if the medicament must be taken regularly during the whole life and treatment is to start early, e.g. when the patient is a child. However, a medicament with a very large and labile molecule normally has a low bioavailability if given subcutaneously, intramuscularly or intradermally, since the uptake is low and degradation is severe. Furthermore, such large proteins may be immunogenic when administered subcutaneously.
Recombinant human Factor VIIa (rFVIIa) is an activated coagulation factor that is useful in the treatment of haemophiliacs that generate neutralising antibodies against Factor VIII or Factor IX. Factor VIII and Factor IX causes severe antibody formation in approximately 10% of the haemophilia patients. The action of rFVIIa (activation of the coagulation system via Factor X) is exerted in the vascular compartment of the body. The route of administration of rFVIIa has until now been intravenously. As a result of the relatively short half-life, administration normally has to be repeated every 2.5 to 3 hours. An alternative form of administration which would result in a reasonable bioavailability and a long lasting absorption phase would allow an increase in dosing intervals and at the same time make self administration possible, thus increasing the convenience for the patient.
Factor VIIa is known to be a glycoprotein with a molecular weight of approximately 50 kDa. It is therefore a sufficiently large molecule to point to the need for direct introduction into the bloodstream, since a very low bioavailability, if any, would be expected. Furthermore quite large doses may be required for an adult, for example during surgery. Consequently, Factor VIIa has conventionally been delivered intravenously to haemophilia A or B patients, either prophylactically or in response to bleeding episodes. Such repeated use of intravenous injections, while necessary to control the disease, has side effects. Repeated injections leads to the vein at the site of injection becoming fibrosed or occluded, a problem especially acute when treating the elderly. Also, when veins are small, as in babies, it may be difficult for the doctor to insert a needle into the vein to inject the required therapeutic dose.
To our knowledge, the only coagulation factor proteins which have been administered by subcutaneous injection is Factor VIII (170-300 kDa) and Factor IX (60 kDa). These coagulation factors, however, are administered in the form of the single-chain zymogens which are not yet activated. These non-activated forms are much more stable than the activated, cleaved forms which are degraded much faster. Subcutaneous injection does not significantly change the pharmacokinetic properties (especially half life) of these two proteins.
Surprisingly, it has now been found that the activated, cleaved and thus more labile form of Factor VII (FVIIa) can be delivered by subcutaneous, intramuscular or intradermal injection with sufficiently transport into the bloodstream in biologically active form and in adequate concentrations. This is especially surprising since FVIIa is tissue factor cofactor and thus would be expected to be caught in the tissues. It has also surprisingly been found that FVIIa shows favourable pharmacokinetic properties (especially half life) when injected subcutaneously, intramuscularly or intradermally.
We have thus developed a composition which makes it possible to administer Factor VIIa subcutaneously, intramuscularly or intradermally and which gives a great advantage for all patients in need of Factor VIIa. This opens the possibility of using FVIIa for prophylactic treatmen

Affiliated with

Also associated with

Rating

Coagulation factor Viia composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Coagulation factor Viia composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coagulation factor Viia composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3287062